Anti‐fibrotic effects of different sources of MSC in bleomycin‐induced lung fibrosis in C57BL6 male mice. Issue 2 (26th August 2020)
- Record Type:
- Journal Article
- Title:
- Anti‐fibrotic effects of different sources of MSC in bleomycin‐induced lung fibrosis in C57BL6 male mice. Issue 2 (26th August 2020)
- Main Title:
- Anti‐fibrotic effects of different sources of MSC in bleomycin‐induced lung fibrosis in C57BL6 male mice
- Authors:
- Periera‐Simon, Simone
Xia, Xiaomei
Catanuto, Paola
Coronado, Ramon
Kurtzberg, Joanne
Bellio, Michael
Lee, Yee‐Shuan
Khan, Aisha
Smith, Robin
Elliot, Sharon J.
Glassberg, Marilyn K. - Abstract:
- ABSTRACT: Background and objective: IPF is a fatal and debilitating lung disorder increasing in incidence worldwide. To date, two approved treatments only slow disease progression, have multiple side effects and do not provide a cure. MSC have promising therapeutic potential as a cell‐based therapy for many lung disorders based on the anti‐fibrotic properties of the MSC. Methods: Critical questions remain surrounding the optimal source, timing and efficacy of cell‐based therapies. The present study examines the most effective sources of MSC. Human MSC were derived from adipose, WJ, chorionic membrane (CSC) and chorionic villi (CVC). MSC were injected into the ageing mouse model of BLM‐induced lung fibrosis. Results: All sources decreased Aschroft and hydroxyproline levels when injected into BLM‐treated mice at day 10 with the exception of CSC cells that did not change hydroxyproline levels. There were also decreases in mRNA expression of αv ‐integrin and TNFα in all sources except CSC. Only ASC‐ and WJ‐derived cells reduced AKT and MMP‐2 activation, while Cav‐1 was increased by ASC treatment as previously reported. BLM‐induced miR dysregulation of miR‐29 and miR‐199 was restored only by ASC treatment. Conclusion: Our data suggest that sources of MSC may differ in the pathway(s) involved in repair. Abstract : MSC derived from adipose, chorion, villi and WJ were compared in their ability to rescue BLM‐induced lung fibrosis. Except for CSC, the fibrotic pathway activation wasABSTRACT: Background and objective: IPF is a fatal and debilitating lung disorder increasing in incidence worldwide. To date, two approved treatments only slow disease progression, have multiple side effects and do not provide a cure. MSC have promising therapeutic potential as a cell‐based therapy for many lung disorders based on the anti‐fibrotic properties of the MSC. Methods: Critical questions remain surrounding the optimal source, timing and efficacy of cell‐based therapies. The present study examines the most effective sources of MSC. Human MSC were derived from adipose, WJ, chorionic membrane (CSC) and chorionic villi (CVC). MSC were injected into the ageing mouse model of BLM‐induced lung fibrosis. Results: All sources decreased Aschroft and hydroxyproline levels when injected into BLM‐treated mice at day 10 with the exception of CSC cells that did not change hydroxyproline levels. There were also decreases in mRNA expression of αv ‐integrin and TNFα in all sources except CSC. Only ASC‐ and WJ‐derived cells reduced AKT and MMP‐2 activation, while Cav‐1 was increased by ASC treatment as previously reported. BLM‐induced miR dysregulation of miR‐29 and miR‐199 was restored only by ASC treatment. Conclusion: Our data suggest that sources of MSC may differ in the pathway(s) involved in repair. Abstract : MSC derived from adipose, chorion, villi and WJ were compared in their ability to rescue BLM‐induced lung fibrosis. Except for CSC, the fibrotic pathway activation was interrupted equally by all treatments; however, each source of MSC used a different mechanism to promote lung repair. See related Editorial … (more)
- Is Part Of:
- Respirology. Volume 26:Issue 2(2021)
- Journal:
- Respirology
- Issue:
- Volume 26:Issue 2(2021)
- Issue Display:
- Volume 26, Issue 2 (2021)
- Year:
- 2021
- Volume:
- 26
- Issue:
- 2
- Issue Sort Value:
- 2021-0026-0002-0000
- Page Start:
- 161
- Page End:
- 170
- Publication Date:
- 2020-08-26
- Subjects:
- bleomycin -- cell‐based therapy -- lung fibrosis -- mesenchymal stem cells -- pulmonary
Respiratory organs -- Diseases -- Periodicals
Respiratory organs -- Periodicals
612.2 - Journal URLs:
- http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=res ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/resp.13928 ↗
- Languages:
- English
- ISSNs:
- 1323-7799
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 7777.666000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 15688.xml